NCT02242942 2025-11-06Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic LeukemiaHoffmann-La RochePhase 3 Completed445 enrolled 22 charts 1 FDA
NCT02475681 2025-08-27ElevateTNAcerta Pharma BVPhase 3 Active not recruiting535 enrolled 19 charts 1 FDA